CRISPR tech market to reach $1.72m by 2023: report
23-11-2018
Allergan to pay Editas $90m for development of CRISPR eye treatment
20-03-2017
Are the Broad Institute’s CRISPR patents too broad?
29-10-2015
jansucko / iStockphoto.com
US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
CRISPR, funding, KSQ Therapeutics, drug candidates, CRISPRomics, drug discovery, T-cell immunotherapy, Flagship Pioneering, Polaris Partners
